Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (referred to as Quoin Pharmaceuticals, Ltd. in the request metadata) on August 6, 2019. The filing reports on the reconvened annual general meeting of shareholders held on the same date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural report regarding shareholder meeting outcomes and does not contain financial statements.
Material Changes
There are no material financial changes reported in this filing. The primary event is the successful passage of all agenda items originally proposed at the annual general meeting by ordinary shareholders and ADS holders.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly confirms the completion of the shareholder meeting agenda.
Key Facts for Investors to Verify
- Confirm the specific agenda items passed at the reconvened annual general meeting by reviewing Exhibit 99.1 referenced in the June 25, 2019 Form 6-K.
- Verify the company's current financial status through its most recent Form 20-F or quarterly reports, as this filing contains no financial data.
- Note the discrepancy between the request metadata name ("Quoin Pharmaceuticals, Ltd.") and the registrant name in the filing ("Cellect Biotechnology Ltd.").